Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Viruses ; 16(4)2024 03 22.
Article in English | MEDLINE | ID: mdl-38675831

ABSTRACT

Data on COVID-19 mortality among patients in intensive care units (ICUs) from Eastern and/or Southern European countries, including Greece, are limited. The purpose of this study was to evaluate the ICU mortality trends among critically ill COVID-19 patients during the first two years of the pandemic in Greece and to further investigate if certain patients' clinical characteristics contributed to this outcome. We conducted a multi-center retrospective observational study among five large university hospitals in Greece, between February 2020 and January 2022. All adult critically ill patients with confirmed COVID-19 disease who required ICU admission for at least 24 h were eligible. In total, 1462 patients (66.35% males) were included in this study. The mean age of this cohort was 64.9 (±13.27) years old. The 28-day mortality rate was 35.99% (n = 528), while the overall in-hospital mortality was 50.96% (n = 745). Cox regression analysis demonstrated that older age (≥65 years old), a body mass index within the normal range, and a delay in ICU admission from symptom onset, as well as worse baseline clinical severity scores upon ICU admission, were associated with a greater risk of death. Mortality of critically ill COVID-19 patients was high during the first two years of the pandemic in Greece but comparable to other countries. Risk factors for death presented in this study are not different from those that have already been described for COVID-19 in other studies.


Subject(s)
COVID-19 , Critical Illness , Hospital Mortality , Intensive Care Units , Humans , COVID-19/mortality , COVID-19/epidemiology , Greece/epidemiology , Male , Female , Middle Aged , Retrospective Studies , Intensive Care Units/statistics & numerical data , Aged , Hospital Mortality/trends , Critical Illness/mortality , SARS-CoV-2 , Risk Factors , Aged, 80 and over , Pandemics , Adult
2.
Future Oncol ; 17(32): 4389-4395, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34431326

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has changed many aspects of our everyday lives and medical practice, including oncology treatment; thyroid cancer surgery is not an exception. The reported number of fine-needle aspirations performed during the first semester of 2020 was significantly reduced. Poorly differentiated, medullary and anaplastic thyroid tumors are considered important indications for immediate surgical intervention. By contrast, most well-differentiated carcinomas present slow growth, and thus surgery can be deferred for a short period of time during which patients are under active surveillance. Thyroid surgeries have decreased during the COVID-19 pandemic. Furthermore, prior to any intervention, negative COVID-19 status - with the use of a nasopharyngeal swab and reverse transcription PCR assay as the gold standard and chest CT scan as a complementary modality in some cases - must be confirmed to achieve a COVID-free pathway. Thorough preoperative assessment regarding both oncological and anatomical aspects should be performed to identify optimal timing for safe management.


Subject(s)
Primary Prevention/methods , Thyroid Neoplasms/surgery , Thyroidectomy/statistics & numerical data , Time-to-Treatment , Triage/methods , Biopsy, Fine-Needle , COVID-19/diagnosis , COVID-19/prevention & control , COVID-19 Testing/methods , Humans , SARS-CoV-2/genetics , Thyroid Gland/pathology , Thyroid Neoplasms/pathology
3.
Expert Rev Med Devices ; 18(1): 75-82, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33307870

ABSTRACT

Background: Papillary thyroid carcinoma is the most common type of thyroid cancer; despite its generally indolent course, patients often develop local post-operative recurrences. Re-operation, however, holds a high complication rate, while at the same time, not all patients benefit from radioiodine ablation. This systematic review investigates the application of laser ablation therapy (LAT) for cervical lymph node metastases as an additional treatment modality.Methods: This systematic review was conducted in accordance with the PRISMA Statement. Medline electronic database and Cochrane Library were searched for eligible articles.Results: Five studies were included in the systematic review. All studies included patients with metastatic lymph nodes from papillary thyroid carcinoma, that were unsuitable for further radioiodine or surgical treatment. Patients were treated with two different LAT devices. Regardless of the utilized assessment modalities, all researchers reported significant outcomes on local disease control. No permanent complications were observed.Conclusions: LAT is relatively safe and effective for the treatment of cervical metastatic lymph nodes in patients with papillary thyroid carcinoma.


Subject(s)
Cervical Vertebrae/pathology , Laser Therapy , Lymph Nodes/pathology , Lymph Nodes/surgery , Lymphatic Metastasis/therapy , Thyroid Cancer, Papillary/pathology , Thyroid Neoplasms/pathology , Humans , Patient Selection , Postoperative Complications/etiology , Thyroid Cancer, Papillary/surgery , Thyroid Neoplasms/surgery , Treatment Outcome
4.
Expert Rev Med Devices ; 17(8): 759-771, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32749167

ABSTRACT

BACKGROUND: Thyroid nodules are common; the majority of them are benign and asymptomatic. Thyroidectomy might be an option; however, the frequency of post-operative complications mandates the development of alternative approaches, such as high-intensity focused ultrasound ablation (HIFU). HIFU induces thermal destruction without penetrating the skin. The present systematic review aims to synthesize all available data, evaluating studies with single-session HIFU therapy and investigating its efficacy. MATERIALS AND METHODS: This systematic review was conducted in accordance with the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and MetaAnalyses). Eligible articles were identified by a search of Medline bibliographic database (PubMed) and Cochrane Library. Out of 39 results, 11 articles were considered to meet the inclusion criteria. RESULTS: All eligible studies included patients with solid or predominantly solid benign thyroid nodules. All patients were treated with the same HIFU device. The success rate of the method was defined in the majority, with the volume reduction rate (VRR) over 50% from baseline. The mean or median VRR ranged from 48.7 to 70.41%, depending on the last follow-up date. No major complications were observed. CONCLUSION: Single-session HIFU is safe and effective for the treatment of benign thyroid nodules.


Subject(s)
High-Intensity Focused Ultrasound Ablation , Thyroid Nodule/diagnostic imaging , Humans , Patient Selection , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...